Prestige Consumer Healthcare (NYSE:PBH) Posts Earnings Results, Beats Expectations By $0.02 EPS

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) released its earnings results on Thursday. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02, Zacks reports. The firm had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Prestige Consumer Healthcare's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.02 EPS. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.700-4.820 EPS.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded up $0.61 during trading hours on Friday, hitting $87.65. The company's stock had a trading volume of 405,208 shares, compared to its average volume of 296,998. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04. The company has a market cap of $4.34 billion, a P/E ratio of 20.53, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The company's 50 day simple moving average is $83.18 and its two-hundred day simple moving average is $81.39.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. StockNews.com downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Friday. Oppenheimer raised their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.